LEO Pharma

LEO Pharma is a global leader in medical dermatology, delivering innovative treatments for skin diseases, building on a century of experience with breakthrough medicines in healthcare. With more than 60 years of specialist clinical development and commercial success in medical dermatology, we have developed deep expertise in one of healthcare’s most complex areas, encompassing over 1,000 conditions, high unmet needs, and diverse treatment approaches.

Source: https://leo-pharma.com/who-we-are/

tralokinumabAdbry

IL-13 inhibitor

Adbry (tralokinumab) is an interleukin-13 antagonist from LEO Pharma for moderate to severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies. It can be used with or without topical corticosteroids.

Tralokinumab is a monoclonal antibody given by subcutaneous injection that binds the cytokine interleukin-13 and blocks its signalling. IL-13 is a key

1 medicine explained